BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.

Antimicrobial Agents and Chemotherapy
B SlocombeR Sutherland

Abstract

BRL 17421 is a new semisynthetic beta-lactam antibiotic with an unusual spectrum of antibacterial activity. The compound exhibits exceptional stability to a wide range of bacterial beta-lactamases and is active against the majority of Enterobacteriaceae, including strains highly resistant to many of the penicillins and cephalosporins currently available. Among the clinical isolates of Enterobacteriaceae tested, the frequency of strains resistant to BRL 17421 was found to be low, and there was a slow rate of emergence of resistance during in vitro studies. BRL 17421 was highly active against Haemophilus influenzae and Neisseria gonorrhoeae, including beta-lactamase-producing strains. The compound was markedly less active against Pseudomonas aeruginosa and Bacteroides fragilis than against the Enterobacteriaceae. Against the gram-positive bacteria, BRL 17421 showed a very low level of activity. BRL 17421 was found to be 85% bound to human serum, and the antibacterial activity was diminished two- to fourfold in the presence of human serum. Against experimental infections in mice, the activity of BRL 17421 reflected the properties observed in vitro. Studies in human volunteers showed unusually high and prolonged serum concentration...Continue Reading

References

Aug 1, 1979·Antimicrobial Agents and Chemotherapy·H C NeuK Kung
Jul 1, 1979·The Journal of Antimicrobial Chemotherapy·M Matthew
Sep 1, 1979·Antimicrobial Agents and Chemotherapy·M BarzaS L Gorbach
Jun 1, 1976·The Journal of Antimicrobial Chemotherapy·R B Sykes, M Matthew
Jan 1, 1973·Advances in Microbial Physiology·M H Richmond, R B Sykes
Aug 1, 1980·Antimicrobial Agents and Chemotherapy·K ShannonI Phillips
May 1, 1980·Antimicrobial Agents and Chemotherapy·C H O'CallaghanS M Harding

❮ Previous
Next ❯

Citations

Feb 1, 1985·European Journal of Clinical Microbiology·P C FuchsR N Jones
Jan 1, 1985·Pharmacology & Therapeutics·R B SykesE A Swabb
Jan 1, 1984·Diagnostic Microbiology and Infectious Disease·P C FuchsC Thornsberry
Dec 20, 2008·The Journal of Antimicrobial Chemotherapy·David M Livermore, Paul M Tulkens
Apr 1, 2009·Antimicrobial Agents and Chemotherapy·Jennifer M Adams-HaduchYohei Doi
Apr 1, 1982·Antimicrobial Agents and Chemotherapy·R BolivarG P Bodey
Jul 1, 1982·Antimicrobial Agents and Chemotherapy·L Verbist
Aug 1, 1982·Antimicrobial Agents and Chemotherapy·D GreenwoodA Eley
Aug 1, 1982·Antimicrobial Agents and Chemotherapy·H Lagast, J Klastersky
Sep 1, 1982·Antimicrobial Agents and Chemotherapy·K Jules, H C Neu
Oct 1, 1982·Antimicrobial Agents and Chemotherapy·H W Van LanduytJ Boelaert
Jan 1, 1984·Antimicrobial Agents and Chemotherapy·L Verbist, J Verhaegen
Sep 1, 1984·Antimicrobial Agents and Chemotherapy·R LabiaM Cole
Nov 1, 1984·Antimicrobial Agents and Chemotherapy·M J BaskerS J White
May 1, 1985·Antimicrobial Agents and Chemotherapy·B NunnP D Chamberlain
Jun 1, 1985·Antimicrobial Agents and Chemotherapy·R J Boon, A S Beale
Feb 1, 1986·Antimicrobial Agents and Chemotherapy·H W Van LanduytB Gordts
May 1, 1986·Antimicrobial Agents and Chemotherapy·W Mandell, H C Neu
Nov 1, 1986·Antimicrobial Agents and Chemotherapy·R L Then, P Angehrn
Jun 14, 2013·Clinical Medicine : Journal of the Royal College of Physicians of London·Alasdair MacGowan, Maha Albur
Jan 1, 1986·Scandinavian Journal of Infectious Diseases·H GorisD van der Waaij
Sep 16, 2010·Expert Opinion on Therapeutic Patents·Karen Bush, Mark J Macielag
Apr 29, 2014·Expert Opinion on Pharmacotherapy·Ilias Karaiskos, Helen Giamarellou
Nov 1, 1982·Toxicology and Applied Pharmacology·P C BillingsC Heidelberger
Jul 19, 2011·Critical Care Research and Practice·Rishi H-P Dhillon, John Clark
Jun 13, 2015·The Journal of Antimicrobial Chemotherapy·Ursula TheuretzbacherGunnar Kahlmeter
Nov 5, 2014·Frontiers in Microbiology·Nadim CassirPhilippe Brouqui
Oct 19, 2014·The Journal of Antimicrobial Chemotherapy·Stewart BarkerThomas J Smith
Mar 15, 2006·The Journal of Antimicrobial Chemotherapy·David M LivermoreNicola Potz
Aug 30, 2017·Clinical Pharmacokinetics·Kevin Alexandre, Bruno Fantin

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.